Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.6050
+0.03055.31%
Volume:4.10M
Turnover:2.46M
Market Cap:134.32M
PE:-2.34
High:0.6253
Open:0.5890
Low:0.5601
Close:0.5745
52wk High:2.93
52wk Low:0.5469
Shares:222.02M
Float Shares:185.00M
Volume Ratio:0.85
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2583
EPS(LYR):-0.2582
ROE:-249.75%
ROA:-52.82%
PB:43.20
PE(LYR):-2.34

Loading ...

Why Humacyte (HUMA) Is Up 5.1% After New DoD Funding Backs Symvess Trauma Use

Simply Wall St.
·
Feb 12

Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential

Simply Wall St.
·
Feb 10

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 10

Humacyte Shares Climb After Pentagon Issues Funding for Vascular Repair Tech

Dow Jones
·
Feb 10

Press Release: Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Dow Jones
·
Feb 09

Humacyte Inc - Symness Is Only FDA-Approved Bioengineered Blood Vessel

THOMSON REUTERS
·
Feb 09

Humacyte Is Maintained at Buy by Benchmark

Dow Jones
·
Jan 21

Humacyte price target lowered to $10 from $11 at Benchmark

TIPRANKS
·
Jan 21

Benchmark Co. Sticks to Its Buy Rating for Humacyte (HUMA)

TIPRANKS
·
Jan 21

While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most

Simply Wall St.
·
Jan 13

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 08

Humacyte Reports Symvess Reduces Costly Complications in Extremity Arterial Injury Repair

Reuters
·
Jan 08

BRIEF-Humacyte Inc Announces Planned Marketing Authorization Application For Symvess In Israel

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 05

Humacyte Inc: Announces Planned Marketing Authorization Application for Symvess in Israel

THOMSON REUTERS
·
Jan 05

Humacyte to Seek Israeli Approval for Symvess in Vascular Trauma Repair

Reuters
·
Jan 05

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 22, 2025

Humacyte Reports Long-Term Success of Symvess in Extremity Trauma Repair

Reuters
·
Dec 22, 2025

BRIEF-Humacyte May Offer And Sell Shares Of Common Stock Of Up To $60 Million From Time To Time Through Td Cowen, Acting As Agent

Reuters
·
Dec 17, 2025

Humacyte: May Offer and Sell Shares of Common Stock of up to $60 Mln From Time to Time Through TD Cowen, Acting as Agent

THOMSON REUTERS
·
Dec 17, 2025